Trial Profile
A Randomised,Double-blind,Placebo-controlled Study to Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride (SY-004) in Chinese Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Feb 2022
Price :
$35
*
At a glance
- Drugs Globalagliatin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Yabao Pharmaceutical Group
- 26 Jan 2022 Results published in the Clinical Therapeutics
- 29 Jan 2018 Status changed from recruiting to completed.
- 06 Jun 2017 New trial record